| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3ab6551dbce22977d355988d5012e888
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate |
2014-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_391d101c19a6fda3d3ba724544099dae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a84af88e7c185455285255b6f495123
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_706fc874f6dcf20d4902a6b3cc783609 |
| publicationDate |
2015-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2015013865-A |
| titleOfInvention |
Cancer immunotherapy composition and method of use thereof |
| abstract |
A cellular composition and method for inducing an immune response against tumor cells. A cellular composition for generating an immune response against cancer in a human subject comprising a tumor antigen, and a cytokine coding sequence and an anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) antibody A cell composition comprising one or more populations of cells genetically modified to express a coding sequence of: The CTLA4 antibody in a 5 ′ to 3 ′ direction, operably linked to the coding sequence of the first strand of the anti-CTLA4 antibody, a proteolytic cleavage site, a sequence encoding a self-processing cleavage site, and the anti-CTLA4 Expressed using a vector comprising the coding sequence of the second chain of the antibody, wherein the sequence encoding the self-processing cleavage site is the coding sequence of the first chain and the second chain of the anti-CTLA4 antibody Inserted between the two. [Selection] Figure 1 |
| priorityDate |
2006-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |